Endurance Technologies Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 20, 2025, 7:01 pm

Competitors of Endurance Technologies Ltd

All Competitor Stocks of Endurance Technologies Ltd

Quarterly Result

Last Updated: August 20, 2025, 11:10 am

Below is a detailed analysis of the quarterly data for Endurance Technologies Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 3,319.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,963.00 Cr. (Mar 2025) to 3,319.00 Cr., marking an increase of 356.00 Cr..
• For Expenses, as of Jun 2025, the value is 2,875.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,541.00 Cr. (Mar 2025) to 2,875.00 Cr., marking an increase of 334.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 444.00 Cr.. The value appears strong and on an upward trend. It has increased from 422.00 Cr. (Mar 2025) to 444.00 Cr., marking an increase of 22.00 Cr..
• For OPM %, as of Jun 2025, the value is 13.00%. The value appears to be declining and may need further review. It has decreased from 14.00% (Mar 2025) to 13.00%, marking a decrease of 1.00%.
• For Other Income, as of Jun 2025, the value is 36.00 Cr.. The value appears to be declining and may need further review. It has decreased from 47.00 Cr. (Mar 2025) to 36.00 Cr., marking a decrease of 11.00 Cr..
• For Interest, as of Jun 2025, the value is 14.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 12.00 Cr. (Mar 2025) to 14.00 Cr., marking an increase of 2.00 Cr..
• For Depreciation, as of Jun 2025, the value is 164.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 142.00 Cr. (Mar 2025) to 164.00 Cr., marking an increase of 22.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 302.00 Cr.. The value appears to be declining and may need further review. It has decreased from 314.00 Cr. (Mar 2025) to 302.00 Cr., marking a decrease of 12.00 Cr..
• For Tax %, as of Jun 2025, the value is 25.00%. The value appears to be increasing, which may not be favorable. It has increased from 22.00% (Mar 2025) to 25.00%, marking an increase of 3.00%.
• For Net Profit, as of Jun 2025, the value is 226.00 Cr.. The value appears to be declining and may need further review. It has decreased from 245.00 Cr. (Mar 2025) to 226.00 Cr., marking a decrease of 19.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 16.09. The value appears to be declining and may need further review. It has decreased from 17.43 (Mar 2025) to 16.09, marking a decrease of 1.34.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: November 15, 2025, 5:26 am

Growth

Last Updated: September 5, 2025, 3:35 am

Balance Sheet

Last Updated: July 25, 2025, 3:17 pm

Below is a detailed analysis of the balance sheet data for Endurance Technologies Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 141.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 141.00 Cr..
• For Reserves, as of Mar 2025, the value is 5,577.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,837.00 Cr. (Mar 2024) to 5,577.00 Cr., marking an increase of 740.00 Cr..
• For Borrowings, as of Mar 2025, the value is 944.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 765.00 Cr. (Mar 2024) to 944.00 Cr., marking an increase of 179.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 2,465.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,128.00 Cr. (Mar 2024) to 2,465.00 Cr., marking an increase of 337.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 9,126.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 7,871.00 Cr. (Mar 2024) to 9,126.00 Cr., marking an increase of 1,255.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 4,058.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,630.00 Cr. (Mar 2024) to 4,058.00 Cr., marking an increase of 428.00 Cr..
• For CWIP, as of Mar 2025, the value is 293.00 Cr.. The value appears strong and on an upward trend. It has increased from 159.00 Cr. (Mar 2024) to 293.00 Cr., marking an increase of 134.00 Cr..
• For Investments, as of Mar 2025, the value is 804.00 Cr.. The value appears strong and on an upward trend. It has increased from 793.00 Cr. (Mar 2024) to 804.00 Cr., marking an increase of 11.00 Cr..
• For Other Assets, as of Mar 2025, the value is 3,971.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,289.00 Cr. (Mar 2024) to 3,971.00 Cr., marking an increase of 682.00 Cr..
• For Total Assets, as of Mar 2025, the value is 9,126.00 Cr.. The value appears strong and on an upward trend. It has increased from 7,871.00 Cr. (Mar 2024) to 9,126.00 Cr., marking an increase of 1,255.00 Cr..

Notably, the Reserves (5,577.00 Cr.) exceed the Borrowings (944.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Endurance Technologies Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 59.46. This value is within the healthy range. It has increased from 48.38 (Mar 24) to 59.46, marking an increase of 11.08.
• For Diluted EPS (Rs.), as of Mar 25, the value is 59.46. This value is within the healthy range. It has increased from 48.38 (Mar 24) to 59.46, marking an increase of 11.08.
• For Cash EPS (Rs.), as of Mar 25, the value is 97.75. This value is within the healthy range. It has increased from 82.07 (Mar 24) to 97.75, marking an increase of 15.68.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 406.46. It has increased from 353.86 (Mar 24) to 406.46, marking an increase of 52.60.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 406.46. It has increased from 353.86 (Mar 24) to 406.46, marking an increase of 52.60.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 821.88. It has increased from 728.04 (Mar 24) to 821.88, marking an increase of 93.84.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 118.58. This value is within the healthy range. It has increased from 100.50 (Mar 24) to 118.58, marking an increase of 18.08.
• For PBIT / Share (Rs.), as of Mar 25, the value is 80.29. This value is within the healthy range. It has increased from 66.80 (Mar 24) to 80.29, marking an increase of 13.49.
• For PBT / Share (Rs.), as of Mar 25, the value is 77.83. This value is within the healthy range. It has increased from 63.77 (Mar 24) to 77.83, marking an increase of 14.06.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 59.46. This value is within the healthy range. It has increased from 48.38 (Mar 24) to 59.46, marking an increase of 11.08.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 59.46. This value is within the healthy range. It has increased from 48.38 (Mar 24) to 59.46, marking an increase of 11.08.
• For PBDIT Margin (%), as of Mar 25, the value is 14.42. This value is within the healthy range. It has increased from 13.80 (Mar 24) to 14.42, marking an increase of 0.62.
• For PBIT Margin (%), as of Mar 25, the value is 9.76. This value is below the healthy minimum of 10. It has increased from 9.17 (Mar 24) to 9.76, marking an increase of 0.59.
• For PBT Margin (%), as of Mar 25, the value is 9.46. This value is below the healthy minimum of 10. It has increased from 8.75 (Mar 24) to 9.46, marking an increase of 0.71.
• For Net Profit Margin (%), as of Mar 25, the value is 7.23. This value is within the healthy range. It has increased from 6.64 (Mar 24) to 7.23, marking an increase of 0.59.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.23. This value is below the healthy minimum of 8. It has increased from 6.64 (Mar 24) to 7.23, marking an increase of 0.59.
• For Return on Networth / Equity (%), as of Mar 25, the value is 14.62. This value is below the healthy minimum of 15. It has increased from 13.67 (Mar 24) to 14.62, marking an increase of 0.95.
• For Return on Capital Employeed (%), as of Mar 25, the value is 17.51. This value is within the healthy range. It has increased from 16.63 (Mar 24) to 17.51, marking an increase of 0.88.
• For Return On Assets (%), as of Mar 25, the value is 9.15. This value is within the healthy range. It has increased from 8.62 (Mar 24) to 9.15, marking an increase of 0.53.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.10. This value is below the healthy minimum of 0.2. It has increased from 0.09 (Mar 24) to 0.10, marking an increase of 0.01.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.15. This value is within the healthy range. It has increased from 0.14 (Mar 24) to 0.15, marking an increase of 0.01.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.36. It has decreased from 1.39 (Mar 24) to 1.36, marking a decrease of 0.03.
• For Current Ratio (X), as of Mar 25, the value is 1.71. This value is within the healthy range. It has increased from 1.69 (Mar 24) to 1.71, marking an increase of 0.02.
• For Quick Ratio (X), as of Mar 25, the value is 1.36. This value is within the healthy range. It has increased from 1.30 (Mar 24) to 1.36, marking an increase of 0.06.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 12.78. This value exceeds the healthy maximum of 8. It has increased from 12.10 (Mar 24) to 12.78, marking an increase of 0.68.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 14.29. This value is below the healthy minimum of 20. It has decreased from 14.46 (Mar 24) to 14.29, marking a decrease of 0.17.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 8.69. This value is below the healthy minimum of 20. It has increased from 8.52 (Mar 24) to 8.69, marking an increase of 0.17.
• For Earning Retention Ratio (%), as of Mar 25, the value is 85.71. This value exceeds the healthy maximum of 70. It has increased from 85.54 (Mar 24) to 85.71, marking an increase of 0.17.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 91.31. This value exceeds the healthy maximum of 70. It has decreased from 91.48 (Mar 24) to 91.31, marking a decrease of 0.17.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 35.63. This value is within the healthy range. It has increased from 33.14 (Mar 24) to 35.63, marking an increase of 2.49.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 18.61. This value is within the healthy range. It has increased from 16.95 (Mar 24) to 18.61, marking an increase of 1.66.
• For Enterprise Value (Cr.), as of Mar 25, the value is 27,559.70. It has increased from 25,975.73 (Mar 24) to 27,559.70, marking an increase of 1,583.97.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.38. This value is within the healthy range. It has decreased from 2.54 (Mar 24) to 2.38, marking a decrease of 0.16.
• For EV / EBITDA (X), as of Mar 25, the value is 16.52. This value exceeds the healthy maximum of 15. It has decreased from 18.38 (Mar 24) to 16.52, marking a decrease of 1.86.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.39. This value is within the healthy range. It has decreased from 2.51 (Mar 24) to 2.39, marking a decrease of 0.12.
• For Retention Ratios (%), as of Mar 25, the value is 85.70. This value exceeds the healthy maximum of 70. It has increased from 85.53 (Mar 24) to 85.70, marking an increase of 0.17.
• For Price / BV (X), as of Mar 25, the value is 4.84. This value exceeds the healthy maximum of 3. It has decreased from 5.17 (Mar 24) to 4.84, marking a decrease of 0.33.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.39. This value is within the healthy range. It has decreased from 2.51 (Mar 24) to 2.39, marking a decrease of 0.12.
• For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has increased from 0.02 (Mar 24) to 0.03, marking an increase of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness